RAPT Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
De winst van RAPT Therapeutics zal naar verwachting dalen met 18% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 82% per jaar. De winst per aandeel zal naar verwachting dalen met 9.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -56.4% zijn.
Belangrijke informatie
-18.0%
Groei van de winst
-9.1%
Groei van de winst per aandeel
Biotechs winstgroei | 28.3% |
Inkomstengroei | 82.0% |
Toekomstig rendement op eigen vermogen | -56.4% |
Dekking van analisten | Good |
Laatst bijgewerkt | 25 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?
Nov 10RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | N/A | -190 | -152 | -66 | 3 |
12/31/2025 | N/A | -87 | -94 | -82 | 8 |
12/31/2024 | N/A | -94 | -89 | -65 | 8 |
9/30/2024 | N/A | -107 | -101 | -101 | N/A |
6/30/2024 | N/A | -120 | -105 | -105 | N/A |
3/31/2024 | N/A | -118 | -106 | -106 | N/A |
12/31/2023 | N/A | -117 | -98 | -97 | N/A |
9/30/2023 | N/A | -109 | -93 | -92 | N/A |
6/30/2023 | N/A | -99 | -89 | -87 | N/A |
3/31/2023 | 1 | -93 | -75 | -74 | N/A |
12/31/2022 | 2 | -84 | -72 | -71 | N/A |
9/30/2022 | 2 | -79 | -70 | -69 | N/A |
6/30/2022 | 3 | -76 | -65 | -64 | N/A |
3/31/2022 | 3 | -73 | -63 | -63 | N/A |
12/31/2021 | 4 | -69 | -62 | -61 | N/A |
9/30/2021 | 4 | -64 | -56 | -56 | N/A |
6/30/2021 | 5 | -60 | -54 | -53 | N/A |
3/31/2021 | 5 | -56 | -46 | -46 | N/A |
12/31/2020 | 5 | -53 | -41 | -40 | N/A |
9/30/2020 | 4 | -53 | -31 | -31 | N/A |
6/30/2020 | 2 | -49 | -33 | -33 | N/A |
3/31/2020 | 1 | -47 | -36 | -36 | N/A |
12/31/2019 | N/A | -43 | -36 | -35 | N/A |
9/30/2019 | N/A | -39 | -42 | -39 | N/A |
6/30/2019 | N/A | -40 | -39 | -36 | N/A |
3/31/2019 | N/A | -37 | -37 | -34 | N/A |
12/31/2018 | N/A | -36 | -36 | -33 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat RAPT de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat RAPT de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat RAPT de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: Er wordt verwacht dat RAPT volgend jaar geen omzet zal hebben.
Hoge groei-inkomsten: Er wordt verwacht dat RAPT volgend jaar geen omzet zal hebben.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat RAPT binnen 3 jaar verliesgevend zal zijn.